Back to Authors

Fernandez, Kathrine C.

A5110215298 | I180857899

Mayo Clinic

Pfizer (United States)

Citations 1

SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC

Future Oncology | October 10, 2023 | Volume: 20 | Issue: 11 | Pages: 653-663

10.2217/fon-2022-1249 | PMID 37815847